ReiThera Srl
12
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.
Role: collaborator
Class II Invariant Chain HCV Vaccine Study
Role: collaborator
Study of GRAd-COV2 for the Prevention of COVID-19 in Adults
Role: lead
Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine
Role: lead
A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals
Role: collaborator
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
Role: collaborator
Immune Response to Respiratory Syncytial Virus (RSV) in Health Care Workers
Role: collaborator
Study of a New MVA Vaccine for Hepatitis C Virus
Role: lead
RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
Role: lead
A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV)
Role: lead
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
Role: lead
Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients
Role: lead
All 12 trials loaded